Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker PRLD · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer NCT07905001 · Breast Cancer, Hormone-receptor-positive Breast Cancer PRT13722, Fulvestrant | PRLD Prelude Therapeutics Incorporated | Phase 1 | Recruiting was not yet recruiting | 242 | Oct 31, 2028 | Registry ↗ |
| Oct 29, 2026 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms NCT07469891 · Polycythemia Vera (PV), Myelofibrosis (MF) PRT12396 | PRLD Prelude Therapeutics Incorporated | Phase 1 | Recruiting | 100 | Apr 2028 | Registry ↗ |
| Feb 2, 2026 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid… NCT06682806 · Advanced Solid Tumor, Esophageal Cancer PRT3789, pembrolizumab | PRLD Prelude Therapeutics Incorporated | Phase 2 | Terminated | 6 | Jan 23, 2026 | Registry ↗ |
| Feb 2, 2026 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors… NCT06560645 · Advanced Solid Tumor, Metastatic Solid Tumor PRT7732 | PRLD Prelude Therapeutics Incorporated | Phase 1 | Terminated | 42 | Jan 28, 2026 | Registry ↗ |
| Jan 26, 2026 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participant… NCT05665530 · Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lym… PRT2527, Zanubrutinib | PRLD Prelude Therapeutics Incorporated | Phase 1 | Completed | 86 | Jun 12, 2025 | Registry ↗ |
| Oct 16, 2025 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors… NCT05639751 · Advanced Solid Tumor, Metastatic Solid Tumor PRT3789, Docetaxel | PRLD Prelude Therapeutics Incorporated | Phase 1 | Completed | 135 | Oct 1, 2025 | Registry ↗ |
| Jul 1, 2024 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors NCT05538572 · Breast Cancer, Glioblastoma PRT3645 | PRLD Prelude Therapeutics Incorporated | Phase 1 | Completed | 22 | Jun 26, 2024 | Registry ↗ |
| Jan 31, 2024 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Ma… NCT05107856 · Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma PRT1419, Azacitidine | PRLD Prelude Therapeutics Incorporated | Phase 1 | Terminated | 21 | Jan 19, 2024 | Registry ↗ |
| Dec 11, 2023 | A Study of PRT2527 in Participants With Advanced Solid Tumors NCT05159518 · Sarcoma, Castrate Resistant Prostate Cancer PRT2527 | PRLD Prelude Therapeutics Incorporated | Phase 1 | Completed | 30 | Dec 6, 2023 | Registry ↗ |
| Apr 5, 2023 | A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas NCT04089449 · Advanced Solid Tumor, Recurrent Glioma PRT811 | PRLD Prelude Therapeutics Incorporated | Phase 1 | Completed | 86 | Mar 28, 2023 | Registry ↗ |
| Mar 28, 2023 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies NCT03886831 · Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refract… PRT543 | PRLD Prelude Therapeutics Incorporated | Phase 1 | Completed | 232 | Nov 16, 2022 | Registry ↗ |
| Mar 15, 2023 | A Study of PRT1419 in Patients With Advanced Solid Tumors NCT04837677 · Sarcoma, Melanoma PRT1419 | PRLD Prelude Therapeutics Incorporated | Phase 1 | Completed | 26 | Feb 6, 2023 | Registry ↗ |
| Nov 15, 2022 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies NCT04543305 · Multiple Myeloma, Acute Myeloid Leukemia PRT1419 | PRLD Prelude Therapeutics Incorporated | Phase 1 | Completed | 16 | Mar 21, 2022 | Registry ↗ |
13 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:11 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances